Navigation Links
ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
Date:5/13/2008

of RA patients. By blocking the CCR1 ligands including the super-activated forms from interacting with the CCR1 receptor, CCX354 is designed to reduce the migration of inflammatory cells leading to rheumatoid arthritis and subsequently joint destruction.

"CCX354 is the third product candidate to enter the clinic from our discovery platform and marks another important milestone for ChemoCentryx," said Thomas J. Schall, Ph.D., President and Chief Executive Officer. "ChemoCentryx has repeatedly shown that it can develop clearly differentiated product candidates by leveraging its technology platform and that it can also advance them expeditiously into clinical development. In less than a year, our product pipeline has expanded from a single ongoing clinical program to now three clinical assets in development."

"We are delighted that this CCR1 antagonist program with ChemoCentryx has progressed to the clinic," said Hugh Cowley, Senior Vice President of GSK's Center of Excellence for External Drug Discovery (CEEDD). "CCX354 may become a promising drug candidate against a number of potential inflammatory diseases and we look forward to seeing the data as it emerges from the clinical trial program."

ChemoCentryx and GSK's Center of Excellence for External Drug Discovery (CEEDD) entered into a multi-product strategic alliance in August 2006 for the discovery, development and commercialization of novel medicines targeting four defined chemokine and chemoattractant receptors for the treatment of a variety of inflammatory disorders. Under the terms of the agreement, ChemoCentryx is responsible for the discovery and development of up to six small molecule drug candidates across four targets through clinical proof-of-concept, at which point GSK will have exclusive options to license each product for further development and commercialization on a worldwide basis. CCX354 is the second compound under the GSK alliance to enter the clinic. ChemoCentryx's lead com
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Go Healthy Initiates Additional Clinical Tests on Cholesterade
2. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
5. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
8. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
9. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Passport Health, one ... , has launched FluFree.com, a website designed to ... For 20 years, Passport Health has provided ... flu. The launch of FluFree.com is designed to address ... the number of people who actually chose to get ...
(Date:9/30/2014)... September 2014 ... Acutus Medical, Inc. ... 3D-Herzkammer-Bildgebungs- und Dipoldichte-Mappingsystem in Echtzeit zur ... komplexen Herzrhythmusstörungen einschließlich Vorhofflimmern führen bzw. ... zusätzlichen Finanzierung über 26,2 Mio. USD ...
(Date:9/30/2014)... , Sept. 30, 2014  Arena Solutions, the ... today announced its Fall 2014 release, which includes ... and Arena DataExtract – and significant ... available products are focused specifically on speeding time ... aggregation of a complete history of tribal knowledge ...
Breaking Medicine Technology:Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 2Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 3Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 4
(Date:9/30/2014)... West Palm Beach, Florida (PRWEB) September 30, 2014 ... of Florida make the treatment of gum disease ... traditional treatments of the past. , “If you’ve ever felt ... into ice cream or sip a cold beverage, it’s possible ... Herbert Salisbury , who is a general dentist in ...
(Date:9/30/2014)... (HealthDay News) -- Medicare should cover low-dose computed tomography ... the disease, a coalition of more than 60 patient ... the Lung Cancer Alliance, the Society of Thoracic Surgeons, ... and the American Society of Clinical Oncology, made its ... Centers for Medicare & Medicaid Services (CMS). Such ...
(Date:9/30/2014)... made progress in reducing the stigma associated with seeking ... stress disorder, but more improvement is still needed, according ... of both the Defense Department and the Veterans Health ... still do not seek needed care for mental ... to promote treatment as a way to reduce stigma, ...
(Date:9/30/2014)... a gene mutation that causes a rare premature aging ... block the rapid, unstoppable cell division that makes cancer ... Michigan and the U-M Health System recently discovered a ... in which precious hematopoietic stem cells can,t regenerate and ... are prone to cancer and bone marrow failure. ...
(Date:9/30/2014)... FDA-approved injectable dermal fillers (i.e. hyaluronic ... in several procedures that are performed to restore ... primarily used for wrinkle treatment of the skin, ... are being used as popular treatments in nonsurgical ... the hands. (1) (2) Dr. Cynthia Elliott of ...
Breaking Medicine News(10 mins):Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 3Health News:Disease decoded: Gene mutation may lead to development of new cancer drugs 2Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 2Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 3Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 4
... Hopkins Kimmel Cancer Center researchers say preliminary studies show ... able to reduce or eliminate the last remaining cancer ... the drug Imatinib mesylate (Gleevec). Gleevec, one of ... CML patients, destroys most leukemic cells in the body, ...
... new study, scientists have searched for mutations in the gene regions ... samples from a single tumour type to be sequenced to date. ... type of kidney cancer, with 102,000 deaths worldwide each year. It ... its nature is remarkably consistent and the majority of cases ...
... arthritis (RA) patients are partially protected by the influenza ... determined that while the flu vaccine is safe, it ... months following rituximab treatment. Previous influenza vaccination in ... some defense to influenza strains. RA activity was ...
... /CNW/ - A recent evaluation by the Centre for Addiction ... alcohol use can be effective in changing drinking behaviours and ... first evaluation of its kind, the study published in ... online screener www.CheckYourDrinking.net, reduced their alcohol consumption by 30% - ...
... of mental health professionals, emergency response experts, and researchers ... results of a study that shows serious emotional disturbances ... Category 3 storm ravaged the Gulf Coast in August ... of the Journal of the American Academy of ...
... the US population becomes increasingly obese while smoking rates continue ... contributor to the burden of disease and shortening of healthy ... the February 2010 issue of the American Journal of ... College of New York calculate that the Quality-Adjusted Life Years ...
Cached Medicine News:Health News:Johns Hopkins researchers say vaccine appears to 'mop up' leukemia cells Gleevec leaves behind 2Health News:Unraveling kidney cancer 2Health News:Unraveling kidney cancer 3Health News:Efficacy of flu vaccine drastically reduced for RA patients treated with rituximab 2Health News:Technology new gateway into treatment for problem alcohol users: Study 2Health News:Obesity now poses as great a threat to quality of life as smoking 2
... oxygen flowmeters., ,Options: , ... S to model number. Example: ... add suffix C to model ... Double Flowmeters with Power Take-Off, ...
... flowmeters., ,Options: , For ... to model number. Example: FMC107S. ... suffix C to model number. ... Flowmeters with Power Take-Off, add ...
... Slim Line Flowmeters with brass and ... security chain, add suffix S to ... Canadian Color-Code, add suffix C to ... Double Flowmeters with Power Take-Off, add ...
... Flowmeters with brass and aluminum body., ... add suffix S to model number. ... add suffix C to model number. ... with Power Take-Off, add PT to ...
Medicine Products: